{"id":768873,"date":"2023-07-11T09:03:57","date_gmt":"2023-07-11T13:03:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/"},"modified":"2023-07-11T09:03:57","modified_gmt":"2023-07-11T13:03:57","slug":"rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/","title":{"rendered":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)<\/b><\/p>\n<p>NEW HAVEN, Conn.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29<sup>th<\/sup> International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 &#8211; September 5. RLYB116 is a novel, potentially long-acting subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases.<\/p>\n<p>\nDetails of the poster presentation are as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Title: <\/b>Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody<sup>\u00ae<\/sup> molecule linked to an Albumod<sup>\u00ae<\/sup> albumin binding domain\n<\/li>\n<li><b>Presenting Author: <\/b>Eric Watsky, M.D., Rallybio\n<\/li>\n<li><b>Abstract Number:<\/b> 36\n<\/li>\n<li><b>Poster Session Date and Time:<\/b> September 3, 2023, from 14:30 &#8211; 16:30 (2:30 p.m. &#8211; 4:30 p.m. ET)\n<\/li>\n<\/ul>\n<p>\nAdditional information about the ICW 2023 Congress is available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ficw2023newcastle.co.uk%2F&amp;esheet=53443940&amp;newsitemid=20230710905244&amp;lan=en-US&amp;anchor=https%3A%2F%2Ficw2023newcastle.co.uk%2F&amp;index=1&amp;md5=5ff9d4d2558fb2778d9294652c568323\">https:\/\/icw2023newcastle.co.uk\/<\/a>.<\/p>\n<p><b>About Rallybio<\/b><\/p>\n<p>\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.<\/p>\n<p>\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut\u2019s Technology Incubation Program in Farmington, Connecticut. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rallybio.com&amp;esheet=53443940&amp;newsitemid=20230710905244&amp;lan=en-US&amp;anchor=www.rallybio.com&amp;index=2&amp;md5=87d65a47a77cd32f73228b72bdf7f896\">www.rallybio.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Frallybio&amp;esheet=53443940&amp;newsitemid=20230710905244&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=dabd0285b061ea4a0fa6cf7e5358e853\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Frallybio&amp;esheet=53443940&amp;newsitemid=20230710905244&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=4c8f27b37d921cf618e1dc44f2cf42b9\">Twitter<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements that are based on our management\u2019s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116, and statements concerning the expected progress, results and plans for RLYB116. The forward-looking statements in this press release are only predictions and are based largely on management\u2019s current expectations and projections about future events and financial trends that management believes may affect Rallybio\u2019s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical studies, and complete such clinical studies and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio\u2019s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio\u2019s Quarterly Report on Form 10-Q for the period ended March 31, 2023, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230710905244\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230710905244\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contacts<br \/>\n<\/b><br \/>Ami Bavishi<br \/>\n<br \/>Head of Investor Relations and Communications<br \/>\n<br \/>475-47-RALLY (Ext. 282)<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:abavishi@rallybio.com\">abavishi@rallybio.com<\/a><\/p>\n<p>\nHannah Deresiewicz<br \/>\n<br \/>Stern Investor Relations, Inc.<br \/>\n<br \/>212-362-1200<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hannah.deresiewicz@sternir.com\">hannah.deresiewicz@sternir.com<\/a><\/p>\n<p><b>Media Contact<br \/>\n<\/b><br \/>Tara DiMilia<br \/>\n<br \/>908-369-7168<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Tara.dimilia@tmstrat.com\">Tara.dimilia@tmstrat.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Connecticut<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Professional Services Other Health Health General Health Pharmaceutical Research Infectious Diseases Science Clinical Trials Finance<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230710905244\/en\/1407047\/3\/Press_Release_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) NEW HAVEN, Conn.&#8211;(BUSINESS WIRE)&#8211; Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 &#8211; September 5. RLYB116 is a novel, potentially long-acting subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases. Details of the poster presentation are as follows: Title: Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody\u00ae molecule linked to an Albumod\u00ae albumin binding &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768873","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) NEW HAVEN, Conn.&#8211;(BUSINESS WIRE)&#8211; Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 &#8211; September 5. RLYB116 is a novel, potentially long-acting subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases. Details of the poster presentation are as follows: Title: Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody\u00ae molecule linked to an Albumod\u00ae albumin binding &hellip; Continue reading &quot;Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T13:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)\",\"datePublished\":\"2023-07-11T13:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/\"},\"wordCount\":766,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/\",\"name\":\"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-11T13:03:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/","og_locale":"en_US","og_type":"article","og_title":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk","og_description":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) NEW HAVEN, Conn.&#8211;(BUSINESS WIRE)&#8211; Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract reporting results from the Phase 1 first-in-human single ascending dose clinical study of RLYB116 has been accepted for presentation as a poster at the 29th International Complement Workshop (ICW), which will take place in Newcastle, UK from August 31 &#8211; September 5. RLYB116 is a novel, potentially long-acting subcutaneously injected inhibitor of C5 in development for the treatment of patients with complement-mediated diseases. Details of the poster presentation are as follows: Title: Phase 1 clinical data for single-dose subcutaneous injection of RLYB116, a C5 blocking Affibody\u00ae molecule linked to an Albumod\u00ae albumin binding &hellip; Continue reading \"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-11T13:03:57+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)","datePublished":"2023-07-11T13:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/"},"wordCount":766,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/","name":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-11T13:03:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230710905244r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rallybio-announces-acceptance-of-abstract-for-rlyb116-at-the-29th-international-complement-workshop-icw\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768873"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768873\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}